<- Go Home
Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Market Cap
$516.9M
Volume
568.9K
Cash and Equivalents
$79.3M
EBITDA
-$35.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.61
52 Week Low
$1.87
Dividend
N/A
Price / Book Value
6.13
Price / Earnings
-10.98
Price / Tangible Book Value
6.13
Enterprise Value
$427.3M
Enterprise Value / EBITDA
-12.03
Operating Income
-$36.1M
Return on Equity
74.47%
Return on Assets
-38.97
Cash and Short Term Investments
$90.6M
Debt
$1.0M
Equity
$84.4M
Revenue
N/A
Unlevered FCF
-$20.0M
Sector
Biotechnology
Category
N/A